Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, ...

Biogen Inc. (NASDAQ:BIIB ) Decentralized Clinical Trials in Focus Conference September 26, 2023 10:00 AM ET Company Participants Stephanie Manson Brown - Head of Clinical Development and Scientific...

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics N...

Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen.

Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 10:40 AM ET Company Participants Christopher Viehbacher - CEO Conference Call Participants Tere...

While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can hel...

Biogen is adding new products to its lineup to reverse its recent revenue decreases. Eli Lilly has a solid portfolio and strong pipeline, and pays a consistent dividend.

Biogen Inc. BIIB, -0.90% shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG NVS, -1.94% spinoff approval for the first biosimila...